Combining p53 mRNA nanotherapy with immune checkpoint blockade reprograms the immune microenvironment for effective cancer therapy

Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study

(2021) Zhenggang Ren et al.   LANCET ONCOLOGY

p53, cancer and the immune response

(2020) Julianna Blagih et al.   JOURNAL OF CELL SCIENCE

Vitamin lipid nanoparticles enable adoptive macrophage transfer for the treatment of multidrug-resistant bacterial sepsis

(2020) Xucheng Hou et al.   Nature Nanotechnology

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

(2020) Richard S. Finn et al.   NEW ENGLAND JOURNAL OF MEDICINE

A tumor‐targeting nanomedicine carrying the p53 gene crosses the blood–brain barrier and enhances anti‐PD‐1 immunotherapy in mouse models of glioblastoma

(2019) Sang‐Soo Kim et al.   INTERNATIONAL JOURNAL OF CANCER

Dual PD ‐1 and VEGFR ‐2 blockade promotes vascular normalization and enhances anti‐tumor immune responses in HCC

(2019) Kohei Shigeta et al.   HEPATOLOGY

Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation

(2019) Lei Miao et al.   NATURE BIOTECHNOLOGY

Synthetic mRNA nanoparticle-mediated restoration of p53 tumor suppressor sensitizes p53-deficient cancers to mTOR inhibition

(2019) Na Kong et al.   Science Translational Medicine

Activation of p53 in Immature Myeloid Precursor Cells Controls Differentiation into Ly6c + CD103 + Monocytic Antigen-Presenting Cells in Tumors

(2018) Madhav D. Sharma et al.   IMMUNITY

Diverse genetic-driven immune landscapes dictate tumor progression through distinct mechanisms

(2018) Marco Bezzi et al.   NATURE MEDICINE

Restoration of tumour-growth suppression in vivo via systemic nanoparticle-mediated delivery of PTEN mRNA

(2018) Mohammad Ariful Islam et al.   Nature Biomedical Engineering

Challenges in the gene therapy commercial ecosystem

(2017) Rahul Kapoor et al.   NATURE BIOTECHNOLOGY

Overcoming sorafenib evasion in hepatocellular carcinoma using CXCR4-targeted nanoparticles to co-deliver MEK-inhibitors

(2017) Yunching Chen et al.   Scientific Reports

Engineering CRISPR–Cpf1 crRNAs and mRNAs to maximize genome editing efficiency

(2017) Bin Li et al.   Nature Biomedical Engineering

p53- and PAI-1-mediated induction of C-X-C chemokines and CXCR2: importance in pulmonary inflammation due to cigarette smoke exposure

(2016) Nivedita Tiwari et al.   AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY

Immunomodulatory Function of the Tumor Suppressor p53 in Host Immune Response and the Tumor Microenvironment

(2016) Yan Cui et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Safety and Efficacy in Advanced Solid Tumors of a Targeted Nanocomplex Carrying the p53 Gene Used in Combination with Docetaxel: A Phase 1b Study

(2016) Kathleen F Pirollo et al.   MOLECULAR THERAPY

CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice

(2015) Yunching Chen et al.   HEPATOLOGY

Long-circulating siRNA nanoparticles for validating Prohibitin1-targeted non-small cell lung cancer treatment

(2015) Xi Zhu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

p53 amplifies Toll-like receptor 5 response in human primary and cancer cells through interaction with multiple signal transduction pathways

(2015) Maria Shatz et al.   Oncotarget

Radiation and SN38 treatments modulate the expression of microRNAs, cytokines and chemokines in colon cancer cells in a p53-directed manner

(2015) Surajit Pathak et al.   Oncotarget

Mutant p53 in Cancer: New Functions and Therapeutic Opportunities

(2014) Patricia A.J. Muller et al.   CANCER CELL

A unique role for p53 in the regulation of M2 macrophage polarization

(2014) L Li et al.   CELL DEATH AND DIFFERENTIATION

Non-Cell-Autonomous Tumor Suppression by p53

(2013) Amaia Lujambio et al.   CELL

Human NK Cells Are Alerted to Induction of p53 in Cancer Cells by Upregulation of the NKG2D Ligands ULBP1 and ULBP2

(2011) S. Textor et al.   CANCER RESEARCH

Translating p53 into the clinic

(2010) Chit Fang Cheok et al.   Nature Reviews Clinical Oncology

Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion

(2009) Francis Rodier et al.   NATURE CELL BIOLOGY

p53 Regulates Toll-Like Receptor 3 Expression and Function in Human Epithelial Cell Lines

(2008) M. Taura et al.   MOLECULAR AND CELLULAR BIOLOGY